MolecuLight Corp., a pioneer in fluorescence imaging technology, has announced a significant advancement in wound care technology with the integration of its MolecuLightDX device into the Intellicure EHR platform. This integration aims to streamline the workflow for wound care clinicians by providing real-time, detailed imaging and measurements of wounds directly within the patient’s electronic health record (EHR).
The MolecuLightDX device, renowned for its ability to detect harmful bacteria and measure wounds digitally, now offers enhanced functionality through its integration with Intellicure’s EHR solutions. Clinicians using Intellicure’s SMART apps or its complete EHR system can now upload both standard and fluorescence images from the MolecuLightDX device directly to the patient’s record. This seamless integration is designed to optimise clinical workflows, improve documentation accuracy, and enhance patient care.
Key Benefits of the Integration
The integration of MolecuLightDX with Intellicure’s EHR platform offers several notable advantages:
- Direct EHR-to-Device Data Transfer: Utilising Wi-Fi, patient data can be transferred directly from the EHR to the MolecuLightDX device.
- Automatic Image Upload: Images captured by the device are automatically uploaded to the EHR, reducing manual data entry.
- Digital Wound Measurement: The integration supports digital measurement of wounds, alongside standard imaging.
- Bacterial Autofluorescence Images: The device captures images indicating the presence and location of harmful bacteria and biofilm in and around wounds.
- Scalable Integration: The system supports multiple MolecuLightDX devices per site, enhancing flexibility and scalability.
Anil Amlani, CEO of MolecuLight Inc., emphasised the importance of this integration: “Optimising our customers’ clinical workflow is a top priority here at MolecuLight. We are proud to announce the inclusion of our MolecuLight platform in Intellicure EHR. The MolecuLightDX is an extensively validated FDA-cleared Class II device that integrates three essential functions: detection of harmful bacteria linked to infection, digital wound measurement, and aid to clinicians in treatment planning. Peer-reviewed publications demonstrate its benefits, including faster healing rates, better resource allocation, cost savings, and improved patient engagement.”
Dr. Caroline Fife, Chief Medical Officer at Intellicure, highlighted the complementary nature of the integration: “Intellicure’s seamless wound care charting platform is a perfect match with MolecuLight. Our platform provides relevant point-of-care clinical practice suggestions, and integrating actionable information about potentially harmful bacteria further enhances patient care and wound outcomes.”
The MolecuLight i
and DX devices are currently the only Class II FDA-cleared, CE-Marked, and Health Canada approved imaging devices available for real-time detection of elevated bacterial burden in wounds. Used globally in leading wound care facilities, these devices are supported by a robust body of clinical evidence.
Intellicure, used extensively by advanced wound care centres in the United States, offers clean clinical workflows, proven regulatory compliance, and high reimbursement rates. For more information, visit Intellicure.com.
